-   Alzheimer\'s disease is prevalent and costly, but can be treated, especially in the early stages;

-   The current approach to dementia diagnosis involves multiple, costly assessments;

-   Positron emission tomography (PET) provides early positive differential diagnosis for Alzheimer\'s disease and other dementias;

-   Brain PET images show characteristic patterns that diffrentiate dementias *([Figure 1](#DialoguesClinNeurosci-2-168-g001){ref-type="fig"}).*

![Characteristic PET patterns for cognitively intact normal persons (left image) and other dementias, including parietal deficits in Alzheimer\'s disease, frontal deficits in Pick\'s disease, irregular cortical and subcortical deficits for multi-infarct dementia, and caudate deficits in Huntington\'s disease. Arrows indicate light gray areas of decreased cerebral glucose metabolism.](DialoguesClinNeurosci-2-168-g001){#DialoguesClinNeurosci-2-168-g001}

-   By contrast, structural imaging (eg, magnetic resonance imaging \[MRI\]) often shows nonspecific atrophy or focal lesions *([Figure 2](#DialoguesClinNeurosci-2-168-g002){ref-type="fig"}).*

![MRI scan (left) and PET scan (right) of the same patient with probable Alzheimer\'s disease. The MRI scans shows generalized atrophy and white matter hyperintensities, which can be nonspecific findings. By contrast, the PET scan shows the parietal and temporal deficits (lighter areas) that are characteristic of Alzheimer\'s disease.](DialoguesClinNeurosci-2-168-g002){#DialoguesClinNeurosci-2-168-g002}

-   The characteristic parietal and temporal deficits of Alzheimer\'s disease may appear several years prior to clinical confirmation of probable diagnosis. These deficits progress along with severity of dementia. Eventually, the frontal cortex becomes hypometabolic as well *([Figure 3](#DialoguesClinNeurosci-2-168-g003){ref-type="fig"}).*

![PET scans showing glucose metabolism at the level of the parietal lobe (upper images) and temporal lobe (lower images). The parietal, temporal, and frontal hypometabolism progresses from early- to late-stage Alzheimer\'s disease, sparing the occipital cortex, deep structures, and the sensorimotor strip.](DialoguesClinNeurosci-2-168-g003){#DialoguesClinNeurosci-2-168-g003}

-   Nondemented older people with the apolipoprotein E4 (APOE-4) genetic risk for Alzheimer\'s disease may have lower parietal metabolism on PET compared with their counterparts without APOE-4 *([Figure 4](#DialoguesClinNeurosci-2-168-g004){ref-type="fig"}).*

![Subject with normal memory performance and the APOE-4 genetic risk for Alzheimer\'s disease (middle scans) showing decreased parietal metabolism (arrowheads), compared with a subject without APOE-4 (left scan). The parietal hypometabolism in a patient with dementia (right scan) is even more pronounced (arrowheads).](DialoguesClinNeurosci-2-168-g004){#DialoguesClinNeurosci-2-168-g004}

-   Longitudinal PET measures of brain metabolism in combination with genetic risk information on Alzheimer\'s disease (eg, APOE genotype) may be useful for determining effects of drugs used to treat age-related cognitive decline.
